Stereotactic radiation improves symptoms versus hippocampal-avoidance whole brain radiation in patients with 5 to 20 brain metastases

This Phase 3 randomized clinical trial evaluated the efficacy of stereotactic radiation versus hippocampal-avoidance whole brain radiation in patients with brain metastases. The study was conducted across four United States-based centers and enrolled a total of 196 randomized patients. The population consisted of individuals with 5 to 20 brain metastases who had not received prior brain-directed radiation. The primary objective was to assess changes in patient-reported symptom severity and interference with daily functioning over a 6-month period postbaseline.

The primary outcome measured the mean weighted patient-reported symptom severity and interference score change over 6 months using the MD Anderson Symptom Inventory-Brain Tumor instrument. In the stereotactic radiation group, the mean change in scores ranged from 2.69 to 2.37, representing a mean change of -0.32. Conversely, the hippocampal-avoidance whole brain radiation group showed a mean change ranging from 2.29 to 3.03, with a mean change of 0.74. The effect size between the two groups was -1.06. The 95% confidence interval for this difference was -1.54 to -0.58, with a P value of less than .001. These results indicate that stereotactic radiation favored hippocampal-avoidance whole brain radiation in reducing symptom burden.

Safety and tolerability were assessed through the monitoring of adverse events. Grade 3-5 adverse events occurred in 12 patients (12%) in the stereotactic radiation group and in 13 patients (13%) in the hippocampal-avoidance whole brain radiation group. Fatigue, a common concern in radiation therapy, was observed as Grade 1-3 adverse events in 27 patients (28%) receiving stereotactic radiation versus 43 patients (44%) receiving hippocampal-avoidance whole brain radiation. Discontinuations due to adverse events were not reported in the study data. Specific tolerability metrics beyond adverse event rates were not reported.

The study design supports the conclusion that stereotactic radiation offers a clinical advantage over hippocampal-avoidance whole brain radiation for the specified patient population. The randomized clinical trial methodology strengthens the causal inference regarding the superiority of stereotactic radiation in improving symptoms and interference with daily functioning. However, the study was limited to four United States-based centers, which may affect the generalizability of the findings to other healthcare settings or populations.

Key methodological limitations were not explicitly detailed in the provided data, though the absence of reported discontinuations and specific tolerability metrics suggests areas where further investigation might be beneficial. The study did not report funding sources or conflicts of interest, which is a standard transparency measure in clinical research. The certainty of the evidence was not explicitly reported, though the P value of less than .001 and the confidence interval excluding zero suggest a statistically significant result.

These findings have direct practice relevance for clinicians managing patients with 5 to 20 brain metastases. The data support the use of stereotactic radiation over hippocampal-avoidance whole brain radiation to improve symptoms and interference with daily functioning. Clinicians should consider these results when making treatment decisions for patients who have not received prior brain-directed radiation. The reduction in fatigue observed with stereotactic radiation (28% versus 44%) may also influence quality-of-life discussions with patients.

Several questions remain unanswered based on this single study. The long-term durability of symptom improvement beyond 6 months was not assessed. The impact of stereotactic radiation on overall survival or progression-free survival was not reported as an outcome. Additionally, the study did not evaluate the efficacy of stereotactic radiation in patients who had received prior brain-directed radiation. Future research should address these gaps to provide a more comprehensive understanding of the role of stereotactic radiation in the management of brain metastases.

In conclusion, this randomized clinical trial provides evidence that stereotactic radiation is superior to hippocampal-avoidance whole brain radiation for reducing symptom severity and interference in patients with 5 to 20 brain metastases. The safety profile was comparable between the two groups, with a lower incidence of Grade 1-3 fatigue in the stereotactic radiation group. Clinicians should interpret these results as supporting the adoption of stereotactic radiation as a standard option for this patient population, pending further validation in broader trials.